U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 191 results

Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ABSOLUTE)


ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wa...
Status:
US Approved Rx (2019)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for...
Status:
US Approved Rx (2023)
First approved in 2009

Class (Stereo):
CHEMICAL (ABSOLUTE)



Levomilnacipran (1S, 2R/F2695) is an enantiomer of milnacipran, a serotonin/norepinephrine (5-HT/NE) reuptake inhibitor. Levomilnacipran is pharmacologically more active as compared with racemic mixture and dextromilnacipran (1R, 2S/F2696). The safe...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (RACEMIC)



Dextromilnacipran (1R, 2S/F2696) is an enantiomer of milnacipran, a serotonin/norepinephrine (5-HT/NE) reuptake inhibitor. Dextromilnacipran is pharmacologically less active as compared with racemic mixture and levomilnacipran (1S, 2R/F2695).
Status:
US Approved Rx (2008)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Tapentadol is the first US FDA-approved centrally acting analgesic having both μ-opioid receptor agonist and noradrenaline (norepinephrine) reuptake inhibition activity with minimal serotonin reuptake inhibition. Tapentadol is indicated for the manag...
Status:
US Approved Rx (2018)
First approved in 2008

Class (Stereo):
CHEMICAL (RACEMIC)



Desvenlafaxine is a dual serotonin and norepinephrine reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios. Desvenlafaxine has demonstrated antidepressant effects in preclinical studies. Pfizer is developing an oral, ...
Status:
US Approved Rx (2018)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)



Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is indicated for the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used ...
Status:
US Approved Rx (2002)
First approved in 2002

Class (Stereo):
CHEMICAL (ABSOLUTE)



Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be re...
Status:
US Approved Rx (2015)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/...
Status:
US Approved Rx (2011)
First approved in 1995

Class (Stereo):
CHEMICAL (RACEMIC)



Tramadol (sold under the brand name Ultram) is a narcotic analgesic proposed for moderate to severe pain. Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors an...